文献速递白血病

肿瘤遗传学突变联合微小残留病可改善儿童T细胞急性淋巴细胞白血病结局预测

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2017-10-19

在220例接受FRALLE2000T方案治疗的儿童T细胞急性淋巴细胞白血病(T-ALL)患者中回顾性检测NOTCH1/FBXW7/RAS和PTEN突变,按肿瘤遗传学分类为低危(gLoR,n=111)和高危(gHiR,n=109);联合第35天微小残留病(MRD)状态分析显示,gHiR患者5年累积复发率(CIR)为36%、无病生存率为60%,gLoR患者分别为11%和89%;肿瘤遗传学分类、MRD和白细胞计数是三个最具区分度的变量。

要点

  • gHiR患者5年CIR为36%、无病生存率60%,gLoR患者分别为11%和89%。
  • 在MRD<10⁻⁴的60%患者中,gHiR的5年CIR为29%,gLoR为4%。
  • 白细胞计数≥200×10⁹/L、gHiR分类且MRD≥10⁻⁴者5年CIR为46%,而三项均低危的58例(30%)患者5年CIR仅2%。

核心结论

  • 在儿童T-ALL中,NOTCH1/FBXW7/RAS/PTEN突变谱是复发的独立预测因素。
  • 联合MRD和白细胞计数≥200×10⁹/L可识别出复发风险显著较低的患者亚组。

研究设计与样本

  • 回顾性检测220例接受FRALLE2000T方案治疗的儿童T-ALL患者的NOTCH1/FBXW7/RAS和PTEN突变。
  • 按突变谱分类:NOTCH1/FBXW7突变且RAS/PTEN胚系者归为肿瘤遗传学低危(gLoR,n=111);NOTCH1/FBXW7胚系且RAS/PTEN胚系突变,或NOTCH1/FBXW7与RAS/PTEN均突变者归为高危(gHiR,n=109)。
  • 191例患者有第35天MRD状态数据。

主要发现

  • gHiR患者5年累积复发率(CIR)为36%、无病生存率为60%;gLoR患者5年CIR为11%、无病生存率为89%。
  • 在MRD<10⁻⁴的60%患者中,gHiR患者5年CIR为29%,gLoR患者为4%。
  • 基于多变量Cox模型和逐步选择,区分度最高的3个变量为肿瘤遗传学分类、MRD和白细胞计数。
  • 白细胞计数≥200×10⁹/L、gHiR分类且MRD≥10⁻⁴的患者5年CIR为46%;而白细胞计数<200×10⁹/L、gLoR分类且MRD<10⁻⁴的58例(30%)患者5年CIR仅为2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk stratification in childhood T-cell acute lymphoblastic leukemia (T-ALL) is mainly based on minimal residual disease (MRD) quantification. Whether oncogenetic mutation profiles can improve the discrimination of MRD-defined risk categories was unknown. Two hundred and twenty FRALLE2000T-treated patients were tested retrospectively for NOTCH1/FBXW7/RAS and PTEN alterations. Patients with NOTCH1/FBXW7 (N/F) mutations and RAS/PTEN (R/P) germ line (GL) were classified as oncogenetic low risk (gLoR; n = 111), whereas those with N/F GL and R/P GL mutations or N/F and R/P mutations were classified as high risk (gHiR; n = 109). Day 35 MRD status was available for 191 patients. Five-year cumulative incidence of relapse (CIR) and disease-free survival were 36% and 60% for gHiR patients and 11% and 89% for gLoR patients, respectively. Importantly, among the 60% of patients with MRD <10-4, 5-year CIR was 29% for gHiR patients and 4% for gLoR patients. Based on multivariable Cox models and stepwise selection, the 3 most discriminating variables were the oncogenetic classifier, MRD, and white blood cell (WBC) count. Patients harboring a WBC count ≥200 × 109/L, gHiR classifier, and MRD ≥10-4 demonstrated a 5-year CIR of 46%, whereas the 58 patients (30%) with a WBC count <200 × 109/L, gLoR classifier, and MRD <10-4 had a very low risk of relapse, with a 5-year CIR of only 2%. In childhood T-ALL, the N/F/R/P mutation profile is an independent predictor of relapse. When combined with MRD and a WBC count ≥200 × 109/L, it identifies a significant subgroup of patients with a low risk of relapse.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Petit A, Trinquand A, Chevret S, et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2017. PMID: 29051182. doi:10.1182/blood-2017-04-778829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。